Joern Aldag compensation by year
HOOKIPA Pharma Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $389,601 | $567,451 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $701,070 | $282,088 |
| Non-equity incentive | $159,737 | $280,888 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $0 |
| Total | $1,250,408 | $1,130,427 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HOOKIPA Pharma Inc. DEF 14A filed April 26, 2024, accession 0001104659-24-052900, and prior-year filings. Open the filing on EDGAR.
How this page was built: the HOOKIPA Pharma Inc. filed document, accession 0001104659-24-052900. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 513,600 | — | $1.00 |
| Option | 12,500 | — | $8.03 |
| Option | 64,875 | — | $12.00 |
| Option | 154,828 | — | $1.66 |
| Option | 154,828 | — | $1.66 |
Per the Outstanding Equity Awards at Fiscal Year-End table in HOOKIPA Pharma Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
HOOKIPA Pharma’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Joern Aldag · this page | Chief Executive Officer | $1,130,427 |
| Christine Baker | Former Chief Operating Officer | $813,399 |
| Reinhard Kandera | Chief Financial Officer | $725,475 |
The full HOOKIPA Pharma compensation record
free company briefThis page is one person within HOOKIPA Pharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HOOKIPA Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.